Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :1666
Small font sizeDefault font sizeIncrease font size
Navigate here
  Search
 
  
Resource links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (198 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed798    
    Printed17    
    Emailed0    
    PDF Downloaded111    
    Comments [Add]    

Recommend this journal

 


 
  Table of Contents  
LETTER TO THE EDITOR
Year : 2014  |  Volume : 51  |  Issue : 4  |  Page : 581
 

Nimotuzumab as a palliative treatment for liver metastasis: The first world report


1 Nutritional Therapy Clinic, MaeFahLuang University Hospital, Bangkok, Thailand; Inter-disciplinary curriculum, Graduate school, Chandrakasem University, Thailand, Thailand
2 Hainan Medical University, China

Date of Web Publication1-Feb-2016

Correspondence Address:
Dr. K Chaiyasit
Nutritional Therapy Clinic, MaeFahLuang University Hospital, Bangkok, Thailand; Inter-disciplinary curriculum, Graduate school, Chandrakasem University, Thailand
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-509X.175369

Rights and Permissions



How to cite this article:
Chaiyasit K, Wiwanitkit V. Nimotuzumab as a palliative treatment for liver metastasis: The first world report. Indian J Cancer 2014;51:581

How to cite this URL:
Chaiyasit K, Wiwanitkit V. Nimotuzumab as a palliative treatment for liver metastasis: The first world report. Indian J Cancer [serial online] 2014 [cited 2019 Aug 24];51:581. Available from: http://www.indianjcancer.com/text.asp?2014/51/4/581/175369


Sir,

Immunotherapy is a new hope in cancer treatment. It is presently used in many cancers. Nimotuzumab is an example of new immunotherapy regimen for management of cancer. It's a humanized monoclonal anti-body specific for EGFR.[1],[2] The mechanism of nimotuzumab is blocking ligand binding and permitting the active receptor conformation.[2] Hence, it is proposed as a new potent anti-cancer agent for any cancers expressing EGFR (such as brain cancer in children, head and neck cancer, etc.).[3] Here, the authors would like to share an experience in using of nimotuzumab treatment in liver metastasis. The case is a female patient (57-years-old) with advanced diseases of breast cancer (adenocarcinoma, stage 4, T4N3M1). This patient has been firstly diagnosed to have cancer for 2 years and got total mastectomy with additional chemotherapy by xeloda (capecitabine) after surgery from other medical center. On the first visit, the liver metastases can be seen with several foci of metastatic nodules with estimated size 1-6 cm. This case was previously failed from treatment with chemotherapy. The standard nimotuzumab treatment (dosage 200 mg/week, intravenously) was given in this case plus therapeutic nutrition and modified diet advise (anti-inflammation diet low-fat high protein). Of interest, at 1 month following up, a significant reduction in size of all liver nodules with estimated size 0.5-3.5 cm can be seen (although it does not disappear). Focusing on the outcome, there is no observed adverse effect during therapy. However, after 2 months of therapy, the patient denied for continuation of drug. This patient survived for 6 months after start receiving nimotuzumab. This can be an evidence that immunotherapy regimen might be a tool for management of liver metastatic in advanced cancer. Interestingly, despite many recent claims on efficacy of nimotuzumab in cancer treatments, there has never been report on its efficacy in management of liver metastasis. Indeed, on biodistribution study, liver is an organ with good distribution of nimotuzumab.[4] Hence, this case might be a good basic information for the possible future clue for palliative management of liver metastases.

 
  References Top

1.
Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: Status and perspectives. Acta Pharmacol Sin 2007;28:1476-93.  Back to cited text no. 1
    
2.
Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009;69:5851-9.  Back to cited text no. 2
    
3.
Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 2008;47:9-19.  Back to cited text no. 3
    
4.
Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, et al. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl Med Commun 2008;29:66-75.  Back to cited text no. 4
    




 

Top
Print this article  Email this article
 

    

  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow